-
1
-
-
84890686350
-
Roflumilast: The new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD
-
Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014;15(1):85–96.
-
(2014)
Expert Opin Pharmacother
, vol.15
, Issue.1
, pp. 85-96
-
-
Tashkin, D.P.1
-
2
-
-
77953105482
-
The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
-
Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–256.
-
(2010)
Pulm Pharmacol Ther
, vol.23
, Issue.4
, pp. 235-256
-
-
Hatzelmann, A.1
Morcillo, E.J.2
Lungarella, G.3
-
4
-
-
84920717687
-
Total and state-specific medical and absenteeism costs of COPD among adults aged $ 18 years in the United States for 2010 and projections through 2020
-
Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged $ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45.
-
(2015)
Chest
, vol.147
, Issue.1
, pp. 31-45
-
-
Ford, E.S.1
Murphy, L.B.2
Khavjou, O.3
Giles, W.H.4
Holt, J.B.5
Croft, J.B.6
-
5
-
-
37349010640
-
Systemic inflammation in chronic obstructive pulmonary disease: The role of exacerbations
-
Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4(8):626–634.
-
(2007)
Proc am Thorac Soc
, vol.4
, Issue.8
, pp. 626-634
-
-
Wouters, E.F.1
Groenewegen, K.H.2
Dentener, M.A.3
Vernooy, J.H.4
-
6
-
-
79956069263
-
Incremental third-party costs associated with COPD exacerbations: A retrospective claims analysis
-
Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14(3):315–323.
-
(2011)
J Med Econ
, vol.14
, Issue.3
, pp. 315-323
-
-
Yu, A.P.1
Yang, H.2
Wu, E.Q.3
Setyawan, J.4
Mocarski, M.5
Blum, S.6
-
7
-
-
84887909801
-
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease
-
Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181.
-
(2013)
BMC Med
, vol.11
, pp. 181
-
-
Wedzicha, J.A.1
Brill, S.E.2
Allinson, J.P.3
Donaldson, G.C.4
-
8
-
-
36749063803
-
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
-
Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081–1087.
-
(2007)
Thorax
, vol.62
, Issue.12
, pp. 1081-1087
-
-
Grootendorst, D.C.1
Gauw, S.A.2
Verhoosel, R.M.3
-
9
-
-
34447310046
-
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
-
Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–161.
-
(2007)
Am J Respir Crit Care Med
, vol.176
, Issue.2
, pp. 154-161
-
-
Calverley, P.M.1
Sanchez-Toril, F.2
McIvor, A.3
Teichmann, P.4
Bredenbroeker, D.5
Fabbri, L.M.6
-
10
-
-
69149103642
-
M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials
-
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694.
-
(2009)
Lancet
, vol.374
, Issue.9691
, pp. 685-694
-
-
Calverley, P.M.1
Rabe, K.F.2
Goehring, U.M.3
Kristiansen, S.4
Fabbri, L.M.5
Martinez, F.J.6
-
11
-
-
79251588730
-
Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD
-
Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
-
(2011)
Respir Res
, vol.12
, pp. 18
-
-
Rennard, S.I.1
Calverley, P.M.2
Goehring, U.M.3
Bredenbroker, D.4
Martinez, F.J.5
-
12
-
-
70249112853
-
-
Wilmington, DE: AstraZeneca Pharmaceuticals LP
-
Daliresp®(roflumilast tablets). US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
-
(2015)
US Prescribing Information
-
-
-
13
-
-
69149098943
-
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials
-
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695–703.
-
(2009)
Lancet
, vol.374
, Issue.9691
, pp. 695-703
-
-
Fabbri, L.M.1
Calverley, P.M.2
Izquierdo-Alonso, J.L.3
-
14
-
-
84893727688
-
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD
-
Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108(2):366–375.
-
(2014)
Respir Med
, vol.108
, Issue.2
, pp. 366-375
-
-
Hanania, N.A.1
Calverley, P.M.2
Dransfield, M.T.3
-
15
-
-
76449090268
-
Roflumilast in chronic obstructive pulmonary disease: Evidence from large trials
-
Cazzola M, Picciolo S, Matera MG. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opin Pharmacother. 2010;11(3):441–449.
-
(2010)
Expert Opin Pharmacother
, vol.11
, Issue.3
, pp. 441-449
-
-
Cazzola, M.1
Picciolo, S.2
Matera, M.G.3
-
16
-
-
57049135358
-
Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis
-
Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416
-
(2008)
JAMA
, vol.300
, Issue.20
, pp. 2407-2416
-
-
Drummond, M.B.1
Dasenbrook, E.C.2
Pitz, M.W.3
Murphy, D.J.4
Fan, E.5
-
17
-
-
84875473420
-
Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: A novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease
-
Moodley T, Wilson SM, Joshi T, et al. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. Mol Pharmacol. 2013;83(4):894–906.
-
(2013)
Mol Pharmacol
, vol.83
, Issue.4
, pp. 894-906
-
-
Moodley, T.1
Wilson, S.M.2
Joshi, T.3
-
18
-
-
84924250308
-
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial
-
Martinez FJ, Calverley PMA, Goehring U-M, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866.
-
(2015)
Lancet
, vol.385
, Issue.9971
, pp. 857-866
-
-
Martinez, F.J.1
Calverley, P.2
Goehring, U.-M.3
Brose, M.4
Fabbri, L.M.5
Rabe, K.F.6
-
21
-
-
33847172367
-
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
-
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
-
(2007)
N Engl J Med
, vol.356
, Issue.8
, pp. 775-789
-
-
Calverley, P.M.1
Erson, J.A.2
Celli, B.3
-
22
-
-
53749102775
-
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
-
Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
-
(2008)
N Engl J Med
, vol.359
, Issue.15
, pp. 1543-1554
-
-
Tashkin, D.P.1
Celli, B.2
Senn, S.3
-
23
-
-
34247561439
-
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial
-
Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555.
-
(2007)
Ann Intern Med
, vol.146
, Issue.8
, pp. 545-555
-
-
Aaron, S.D.1
Vandemheen, K.L.2
Fergusson, D.3
-
24
-
-
84903602640
-
Long-acting bronchodilators in COPD: Where are we now and where are we going?
-
Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):110–120.
-
(2014)
Breathe
, vol.10
, Issue.2
, pp. 110-120
-
-
Cazzola, M.1
Page, C.2
-
25
-
-
84878507499
-
Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation
-
Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation. COPD. 2013;10(3):378–389.
-
(2013)
COPD
, vol.10
, Issue.3
, pp. 378-389
-
-
Rennard, S.1
Thomashow, B.2
Crapo, J.3
-
26
-
-
84939464236
-
Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
-
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639.
-
(2015)
Lancet Respir Med
, vol.3
, Issue.8
, pp. 631-639
-
-
Chen, W.1
Thomas, J.2
Sadatsafavi, M.3
Fitzgerald, J.M.4
-
27
-
-
84871698675
-
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol
-
Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012;7:375–382
-
(2012)
Int J Chron Obstruct Pulmon Dis
, vol.7
, pp. 375-382
-
-
Calverley, P.M.1
Martinez, F.J.2
Fabbri, L.M.3
Goehring, U.M.4
Rabe, K.F.5
|